![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ZEN-3694 (ZEN003694), orally bioavailable small molecule, in initro studies selectively binds to BET proteins with >20 fold selectivity over non-BET bromodomains inhibiting interaction of acetylated histone peptide with IC50 values in low nM range.
Lead Product(s): ZEN003694,Talazoparib
Therapeutic Area: Oncology Product Name: ZEN-3694
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
The combination regimen of ZEN-3694 (ZEN003694) + talazoparib has shown promising clinical activity in a mTNBC patient population with significant unmet need. This combination is active with a manageable safety profile and warrants continued clinical evaluation.
Lead Product(s): ZEN-3694,Talazoparib
Therapeutic Area: Oncology Product Name: ZEN003694
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
The data from the Phase 1b/2 trial has shown that the ZEN003694 (ZEN-3694) plus talazoparib combination regimen induced durable responses in tumors of TNBC patients which do not harbor mutations in BRCA1/2.
Lead Product(s): ZEN-3694,Talazoparib
Therapeutic Area: Oncology Product Name: ZEN003694
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
First clinical Study to Combine ZEN-3694 with BMS’s immune checkpoint inhibitors nivolumab and ipilimumab for treatment of ovarian cancer.
Lead Product(s): ZEN-3694,Nivolumab,Ipilimumab
Therapeutic Area: Oncology Product Name: ZEN-3694
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Division of Cancer Treatment and Diagnosis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2020
Details:
Merck, Pfizer, UCSF and Newsoara join the list of collaborators involved in Zenith's development of ZEN-3694 in epigenetic combination therapy programs.
Lead Product(s): ZEN003694,Enzalutamide,Pembrolizumab
Therapeutic Area: Oncology Product Name: ZEN-3694
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020